ReviewMolecular biology reports2025
PDCD4: A critical regulator in leukemic signaling networks and its therapeutic potential.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Programmed cell death 4 (PDCD4) is a tumor suppressor characterized by its MA3 domain-mediated binding to eIF4A, which suppresses protein synthesis. Its primary functions include inhibiting cell proliferation, invasion, and metastasis, as well as promoting apoptosis. Leukemia is a clonally hematologic malignancy whose pathogenesis is driven primarily by the aberrant activation of key signaling pathways. These dysregulated signals promote enhanced self-renewal, uncontrolled proliferation, impaired differentiation, and blocked apoptosis, collectively arresting leukemic cells at various stages of development. Recent studies have demonstrated a close association between PDCD4 and leukemia development, indicating that PDCD4 regulates this process mainly by participating in abnormally activated signaling pathways. This review examines the expression and regulation of PDCD4 in leukemia, with a focus on its role as a molecular hub that connects the JAK/STAT, PI3K/AKT, and MAPK signaling pathways into a comprehensive network of leukemia pathways. Furthermore, the potential value of PDCD4 in the treatment of leukemia is discussed.
Indexed as
Identifiers
41351720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.